التفاصيل البيبلوغرافية
| العنوان: |
Preoperative levosimendan in coronary surgery in patients with severe ventricular dysfunction : Does it make sense? Levosimendán preoperatorio en cirugía coronaria con disfunción ventricular severa: ¿tiene sentido? |
| المؤلفون: |
Roselló-Díez, Elena, Astrosa, E., Casellas, Sandra, Taurón, Manel, Galán, Josefina, Ginel, Antonino, Montiel, José |
| سنة النشر: |
2021 |
| المجموعة: |
Universitat Autònoma de Barcelona: Dipòsit Digital de Documents de la UAB |
| مصطلحات موضوعية: |
Simendan, Ischemic preconditioning myocardial, Cytoprotection, Myocardial revascularization, Ventricular dysfunction |
| الوصف: |
Introduction and objectives: Numerous studies have demonstrated the benefit of levosimendan in patients with chronic and acute heart failure. However, when it comes to its preoperatory use in coronary by-pass surgery in patients with severe ventricular dysfunction, there are some contradictory results. The objective of this study is assessing preconditioning efficiency with levosimendan in surgical myocardial revascularization in patients with severe ventricular dysfunction. Methods: We design a propensity score-matched cohort study. The study included patients with a LVEF less or equal to 35% who underwent isolated coronary artery by-pass grafting or associated to ischemic/functional mitral surgery from January 2009 to October 2019. They were split into two cohorts whether they received levosimendan preoperatively (Levo) or not (NoLevo); after matching there were 64 patients per cohort. Outcome variables were postoperative morbi-mortality, readmission and follow-up mortality. Statistical analysis: categorical data were compared with a Chi-square or Fisher exact test, and quantitative data with a t-Student or W-Wilcoxon tests. RR/HR were estimated for assessing the association between preoperative use of levosimendan and outcomes. Results: Preoperative levosimendan use did not decreased in-hospital mortality (RR = 0,86, p = 0.770), and neither do hospital stay, nor postoperative complications. Event-free survival was similar between cohorts in terms of cardiological readmissions, all-cause and cardiological follow-up mortality. Conclusions: Our results do not support the widespread use of levosimendan previously to myocardial revascularization surgery in patients with severe ventricular dysfunction. |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
application/pdf |
| اللغة: |
Spanish; Castilian |
| تدمد: |
11340096 |
| Relation: |
Cirugia Cardiovascular; Vol. 28 Núm. 3 (enero 2021), p. 136-143; https://ddd.uab.cat/record/269847; urn:10.1016/j.circv.2020.10.013; urn:oai:ddd.uab.cat:269847; urn:scopus_id:85097684901; urn:articleid:11340096v28n3p136 |
| الاتاحة: |
https://ddd.uab.cat/record/269847 |
| Rights: |
open access ; Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. ; https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| رقم الانضمام: |
edsbas.C6E762CC |
| قاعدة البيانات: |
BASE |
Full Text Finder